27Oct 2023
Eisai's Leqembi: Subcutaneous Injection Equals Intravenous Efficacy in Alzheimer's Treatment

Eisai's Leqembi: Subcutaneous Injection Equals Intravenous Efficacy in Alzheimer's Treatment

Japanese drugmaker Eisai presented data comparing subcutaneous injection of its Alzheimer's drug Leqembi to the IV form. The study, involving 72 early Alzheimer's patients, showed the injected version removed brain plaques as effectively as IV, with the potential for at-home treatment. After six months, the shot form removed 14% more amyloid than the approved IV. However, serious side effects were higher in the subcutaneous group, though Eisai argued safety consistency due to the small sample size. Eisai and Biogen plan U.S. approval for Leqembi based on this data. Additionally, a study found that 60% of early Alzheimer's patients with low tau levels showed cognitive improvement with the drug, supporting early intervention efforts.

  • #family health

Like

Save

Share